Sonoran Biosciences Announces Issuance of a Second US Patent for Its SB Gel Extended-Release Technology
TEMPE, Ariz., Sep. 24, 2024 — Sonoran Biosciences (“Sonoran” or the “Company”), a preclinical-stage pharmaceutical company developing innovative hospital-based products for the treatment of surgical site infections and postoperative pain, announced today the issuance of the Company’s second United States Patent “Temperature-Responsive Degradable Hydrogels.” The patent number is 12,097,260. The patent builds upon Sonoran’s previously awarded US patent and includes claims related to composition of therapeutic systems based on Sonoran’s novel polymers, including for extended release of local anesthetics and antimicrobials. The claims additionally encompass various product presentations to facilitate preparation and dispensing of SB Gel-based extended release formulations.
About Sonoran Biosciences
Sonoran Biosciences, Inc. is a privately held specialty pharmaceutical company developing sustained release formulations for the treatment of postoperative pain and surgical site infection (SSI). Sonoran’s products are based on its proprietary SB Gel, an injectable carrier that forms a solid gel in the body, releases drugs over multiple days, and dissolves after the drugs are released. Sonoran’s lead products are SBG004, a long-acting formulation of bupivacaine for postoperative pain, and SBG003, a fixed-dose combination of tobramycin and vancomycin for surgical site infection.
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.